Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib.

The transformation of lung adenocarcinoma to combined small cell lung cancer is a rare mechanism of acquired resistance to tyrosine kinase inhibitors. This case describes this mechanism in a pleural effusion of a young patient treated with osimertinib for 18 months.